| IO102-IO103 / IO Biotech |
| Not yet recruiting | 2 | 30 | Europe | IO102 + Montanide ISA 51 VG Sterile, IO103 + Montanide ISA 51 VG Sterile, IO102-IO103 + Montanide ISA 51 VG Sterile, IO102, IO103, IO102-IO103, Emulsion for emulsion for injection, Emulsion for injection | Cliniques universitaires Saint-Luc, IoBiotech ApS | Head and neck cancer elective for surgery, Head and neck cancer elective for surgery, Diseases [C] - Cancer [C04] | | | | |
2021-003026-69: A study investigating the use of IO102-IO103 in combination with pembrolizumab for patients with metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head and Neck (SCCHN), or metastatic Urothelial Bladder Cancer (mUBC) |
|
|
| Not yet recruiting | 2 | 90 | Europe | IO102-IO103 + Montanide ISA 51 VG Sterile, Emulsion for injection | IO Biotech ApS, IO Biotech ApS | Metastatic Non-Small Cell Lung Cancer (NSCLC), Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC) cáncer de pulmón no microcítico (CPNM) metastásico, carcinoma de células escamosas de cabeza y cuello (CCECC) metastásico, carcinoma urotelial de vejiga metastásico (CUVm), Lung Cancer, Head and Neck Cancer, Bladder Cancer Cáncer de pulmón, cáncer de cabeza y cuello, cáncer de vejiga, Diseases [C] - Cancer [C04] | | | | |
KEYNOTE-D38, NCT05077709: IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC |
|
|
| Recruiting | 2 | 90 | Europe, US | IO102-IO103 in combination with pembrolizumab | IO Biotech, Theradex, Almac, NeoGenomics, Merck Sharp & Dohme LLC | Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder | 04/24 | 11/24 | | |
NCT04445064: Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. |
|
|
| Recruiting | 2 | 17 | Europe | IO102, IO103 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Oropharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma | 06/24 | 06/24 | | |
KEYNOTE-E40, NCT05280314: Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors |
|
|
| Recruiting | 2 | 60 | Europe, US, RoW | IO102-IO103, Pembrolizumab KEYTRUDA® | IO Biotech, Theradex, Almac, Merck Sharp & Dohme LLC | Melanoma, Squamous Cell Carcinoma of Head and Neck | 04/25 | 01/27 | | |
NCT05912244: A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma |
|
|
| Recruiting | 2 | 43 | US | IO102/IO103, Nivolumab-Relatlimab | Memorial Sloan Kettering Cancer Center, IO Biotech | Melanoma | 06/27 | 06/27 | | |
| Recruiting | 1/2 | 50 | Europe | Nivolumab, Opdivo, PD-L1/IDO peptide vaccine, IO102/IO103 peptide vaccine | Inge Marie Svane | Metastatic Melanoma | 04/23 | 04/23 | | |
